FDA-Grants-Accelerated-Approval-to-Hyrnuo-for-Nonsquamous-NSCLC

Originally published by our sister publication Clinical Oncology NewsBy Clinical Oncology News StaffThe FDA granted accelerated approval to sevabertinib (Hyrnuo, Bayer HealthCare), a kinase inhibitor, for adults with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD)-activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.FDA also approved the Oncomine Dx